Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Medtronic's Sphere-9 catheter shows 65.5% success in treating ventricular tachycardia at 6 months, FDA grants breakthrough status.
MDT
$80.57
+$0.10 +0.12%

Medtronic's Sphere-9 catheter shows 65.5% success in treating ventricular tachycardia at 6 months, FDA grants breakthrough status.

Market News
25 Apr 2026
PRNewsWire
View Source
Bullish
pluang ai news

Medtronic announced promising six-month results from its Sphere-9 catheter used to treat sustained monomorphic ventricular tachycardia (VT), with 65.5% of patients free from VT recurrence. The FDA granted the device Breakthrough Device Designation, speeding its regulatory review. Additionally, the Sphere-360 catheter showed 100% lesion durability in atrial fibrillation patients in Europe. Medtronic has also begun enrolling patients in a new trial to evaluate the Sphere-9 catheter for repeat atrial fibrillation procedures, signaling ongoing investment in expanding treatment options for cardiac arrhythmias.

More News (MDT)

Global blood glucose monitoring market to nearly double to $39.4B by 2035 with 8.9% CAGR driven by AI and home care trends

Global blood glucose monitoring market to nearly double to $39.4B by 2035 with 8.9% CAGR driven by AI and home care trends

The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...

Market News
Bullish
2 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App